HC Wainwright Reiterates Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST)

HC Wainwright reissued their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a research report released on Monday morning, Benzinga reports. They currently have a $25.00 target price on the stock.

Separately, Rodman & Renshaw started coverage on shares of Milestone Pharmaceuticals in a report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price objective on the stock.

Milestone Pharmaceuticals Price Performance

Shares of MIST opened at $1.46 on Monday. The firm has a market capitalization of $77.76 million, a PE ratio of -1.17 and a beta of 1.72. The company has a debt-to-equity ratio of 1.61, a current ratio of 19.13 and a quick ratio of 19.13. Milestone Pharmaceuticals has a 1-year low of $1.12 and a 1-year high of $3.52. The company’s fifty day moving average price is $1.47 and its 200-day moving average price is $1.53.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. On average, equities research analysts predict that Milestone Pharmaceuticals will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIST. BNP Paribas Financial Markets boosted its holdings in Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock valued at $30,000 after purchasing an additional 10,800 shares during the last quarter. Valeo Financial Advisors LLC boosted its holdings in Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Lion Point Capital LP boosted its holdings in Milestone Pharmaceuticals by 1.7% in the second quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock valued at $3,089,000 after purchasing an additional 40,000 shares during the last quarter. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.